Plasma concentrations of von Willebrand factor and intracellular adhesion molecule-1 for prediction of outcome after successful cardiopulmonary resuscitation

被引:26
作者
Geppert, A [1 ]
Zorn, G [1 ]
Delle-Karth, G [1 ]
Koreny, M [1 ]
Siostrzonek, P [1 ]
Heinz, G [1 ]
Huber, K [1 ]
机构
[1] Univ Vienna, Dept Cardiol, Vienna, Austria
关键词
von Willebrand factor; intracellular adhesion molecule; cardiopulmonary resuscitation; outcome; organ dysfunction; organ failure;
D O I
10.1097/01.CCM.0000054861.69462.B5
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: Ischemia/reoxygenation following cardiopulmonary resuscitation might cause endothelial injury/activation that could contribute to an adverse outcome after cardiopulmonary resuscitation. We studied plasma concentrations of von Willebrand factor (vWF) antigen and soluble intracellular adhesion molecule (sICAM)-1 as markers of a generalized endothelial injury/activation in relation to outcome after cardiopulmonary resuscitation. Design: Retrospective study on stored plasma samples. Setting: Intensive care unit at a university hospital. Patients: Thirty-five patients who survived >24 hrs after in- or out-of-hospital cardiopulmonary resuscitation and 15 noncritically ill control patients. Interventions: Blood sampling. Measurements and Main Results: Plasma concentrations of vWF antigen and sICAM-1 on day 2 after cardiopulmonary resuscitation were higher in patents than in controls (p < .001 and p = .001, respectively). In-hospital cardiopulmonary resuscitation, cardiopulmonary resuscitation duration greater than or equal to15 mins, severe cardiovascular failure, and renal dysfunction/failure at the time of blood sampling were associated with significant elevations in vWF antigen and sICAM-1 concentrations. Patients with an unfavorable outcome after cardiopulmonary resuscitation (cerebral performance category :3) exhibited higher vWF antigen and sICAM-1 concentrations than patients good outcome (cerebral performance category 1-2; p < .001 and p = .097, respectively). Renal dysfunction/failure, severe cardiovascular failure, systemic inflammatory response syndrome, and cardiopulmonary resuscitation duration 15 mins were also associated with higher adverse outcome rates. Combination of these four variables into a cardiac arrest risk score (levels 0-4) showed adverse outcome rates of 100, 56, and 0% in patients with arrest scores of 4, 2-3, and 0-1, respectively. A vWF antigen concentration >166% was an independent predictor of outcome after cardiopulmonary resuscitation (p = .002) and was associated with increased adverse outcome rates in patients with cardiac arrest risk scores of 2-3. Furthermore, both vWF antigen concentrations >166% and sICAM-1 concentrations >500 ng/mL had 1000/6 specificity for an adverse outcome in patients after out-of-hospital cardiopulmonary resuscitation but were less predictive in patients after in-hospital cardiopulmonary resuscitation. Conclusions: vWF antigen and sICAM-1 might be useful adjunctive variables for early determination of outcome in patients after successful out-of-hospital cardiopulmonary resuscitation.
引用
收藏
页码:805 / 811
页数:7
相关论文
共 42 条
[1]  
ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225
[2]  
ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397
[3]   Soluble intercellular adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von Willebrand factor in stroke [J].
Blann, A ;
Kumar, P ;
Krupinski, J ;
McCollum, C ;
Beevers, DG ;
Lip, GYH .
BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 (05) :277-284
[4]   Neutrophil elastase, von Willebrand factor, soluble thrombomodulin and percutaneous oxygen in peripheral atherosclerosis [J].
Blann, AD ;
Seigneur, M ;
Adams, RA ;
McCollum, CN .
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 1996, 12 (02) :218-222
[5]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[6]  
Böttiger BW, 2001, CIRCULATION, V103, P2694
[7]  
Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO
[8]  
2-6
[9]  
Catto AJ, 1997, THROMB HAEMOSTASIS, V77, P1104
[10]  
CHIGNARD M, 1993, EUR RESPIR J, V6, P791